



GlaxoSmithKline to Manufacture Vaccines in Nashik, India GSK's first vaccine facility in India

Nashik, February 22, 2005: The foundation stone of the state-of-the-art vaccines facility conforming to international current Good Manufacturing Practices (cGMP) norms was laid today by Mr. Patrick Florent, Vice President, Global Industrial Operations, GlaxoSmithKline Biologicals. This facility is expected to commence operations early 2006.

GSK is a world leader in vaccines. Vaccines for India are currently developed, produced, filled and packaged at the Company's vaccines headquarters and manufacturing facility at Rixensart, Belgium. GSK's vaccines pipeline is the best in the world, particularly for vaccines against diseases such as Rotavirus related gastroenteritis, Malaria, TB, Dengue Fever, Hepatitis E and Typhoid, which will benefit the developing world the most.

The new Indian vaccine facility will be located adjacent to the Company's existing pharmaceutical plant at Maharashtra Industrial Development Corporation (MIDC), Ambad, Nashik. This will be GSK's first manufacturing site to co-house a pharmaceutical and vaccine manufacturing.

Speaking at the occasion, Mr. Florent said, "Vaccination programmes are one of the most effective public health measures, second only to clean drinking water. I am happy that a new vaccine plant, conforming international standards, is being set up at Nashik. People of India will soon be able to benefit from high quality vaccines from a state-of-the-art international standard vaccine facility located in India for protection against many infectious diseases."

Mr. S. Kalyanasundaram, Managing Director, GSK India and Vice President, South Asia, GSK International, said, "This day marks a historic milestone for GSK in India. Unlike developed countries, disease burden from infectious diseases falls on patients in developing countries due to the lack of an adequate social security system to cover the costs of treatment. This makes use of Preventive Health Technologies (PHTs) highly valuable in Indian context." He further added, "This new vaccine facility reflects the Company's commitment to India and recognises the high quality skills and science base in India. As India continues to improve the framework it offers to investors, especially in the field of protecting intellectual property rights, its attractiveness to investors such as GSK will grow."

The new GSK vaccine facility in Nashik conforms to cGMP norms. The quality control will be under the close supervision of GSK Biologicals, Belgium. The manufacturing facility, when completed, will possess all attributes of the most modern vaccine manufacturing plants globally. The plant is being built to cater to Indian market needs which could be expanded for meeting the requirements of neighbouring countries. The creation of this plant demonstrates GSK's commitment to the people of India.